In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma von Ambrogio, C, Barbacid, M, Santamaría, D

Volltext

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer von Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S.J., Nishino, M., Sholl, L.M., Barbie, D.A., Negrao, M.V., Zhang, J., Cherniack, A.D., Heymach, J.V., Meyerson, M., Ambrogio, C., Jänne, P.A., Arbour, K.C., Pinato, D.J., Skoulidis, F., Schoenfeld, A.J., Awad, M.M., Luo, J.

Volltext

ES28.03 Mechanisms of Resistance to KRAS G12C Inhibitors von Ambrogio, C.

Volltext

IA02 Insights into KRAS Biology to Identify Potential Therapeutic Strategies von Ambrogio, C.

Volltext

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency von Ceccon, M, Merlo, M E Boggio, Mologni, L, Poggio, T, Varesio, L M, Menotti, M, Bombelli, S, Rigolio, R, Manazza, A D, Di Giacomo, F, Ambrogio, C, Giudici, G, Casati, C, Mastini, C, Compagno, M, Turner, S D, Gambacorti-Passerini, C, Chiarle, R, Voena, C

Volltext

191: Heterogeneity among early-stage K-Ras driven lung adenocarcinoma predicts tumor aggressiveness and identifies Ddr1 as a therapeutic target von Ambrogio, C, Gomez, G, Santamaria, D, Barbacid, M

Volltext

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1 von Voena, C, Di Giacomo, F, Panizza, E, D'Amico, L, Boccalatte, F E, Pellegrino, E, Todaro, M, Recupero, D, Tabbò, F, Ambrogio, C, Martinengo, C, Bonello, L, Pulito, R, Hamm, J, Chiarle, R, Cheng, M, Ruggeri, B, Medico, E, Inghirami, G

Volltext

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma von Ambrogio, Chiara, Gómez-López, Gonzalo, Falcone, Mattia, Vidal, August, Nadal, Ernest, Crosetto, Nicola, Blasco, Rafael B, Fernández-Marcos, Pablo J, Sánchez-Céspedes, Montserrat, Ren, Xiaomei, Wang, Zhen, Ding, Ke, Hidalgo, Manuel, Serrano, Manuel, Villanueva, Alberto, Santamaría, David, Barbacid, Mariano

Volltext

25 Proffered Paper: Involvement of Epigenetics in the Early Stages of NSCLC Development von Ambrogio, C, Carmona, F.J, Santamaria, D, Gomez, G, Lozano, M, Mainardi, S, Nieto, P, Kocher, O, Esteller, M, Barbacid, M

Volltext

The RAF/MEK clamp VS-6766 shows strong anti-tumor activity across multiple MAPK pathway alterations, with a preferential effect on KRAS G12V von Coma, S., Musteanu, M., Mira, A., Caffarra, C., Morrison, D., Ambrogio, C., Barbacid, M., Pachter, J.

Volltext

The EGFR family members sustain the neoplastic phenotype of ALK plus lung adenocarcinoma via EGR1 von Voena, C, Di, Giacomo F, Panizza, E, D'Amico, L, Boccalatte, FE, Pellegrino, E, Todaro, M, Recupero, D, Tabbo, F, Ambrogio, C

Volltext

2255P Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers von Ricciuti, B., Alessi, J.V., Wang, X., Pecci, F., Di Federico, A., Gandhi, M., Makarem, M., Sholl, L., Jänne, P.A., Ambrogio, C., Awad, M.M.

Volltext

PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment von Ambrogio, C., Jänne, P.A.

Volltext

239 (PB227): KRAS pharmacological blockade elicits tumoral homologous recombination deficiency exploitable with PARP inhibitors von Welch, C., Novoa, G., Llorente, S. Llorente, Ramos, A. Santos, Sogari, A., Lagos, A. Fernandez, Fileu, I., Guruceaga, E., Calvo, A., Otegui, N. Bakartxo, Battuello, P., Crisafulli, G., Ambrogio, C., Santamaria, D., Bardelli, A., Tian, T., Ferrer, I., Russo, M., Vicent, S.

Volltext

Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo von KARPATKIN, S, PEARLSTEIN, E, AMBROGIO, C, COLLER, B. S

Volltext

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas von Piva, Roberto, Chiarle, Roberto, Manazza, Andrea D., Taulli, Riccardo, Simmons, William, Ambrogio, Chiara, D'Escamard, Valentina, Pellegrino, Elisa, Ponzetto, Carola, Palestro, Giorgio, Inghirami, Giorgio

Volltext

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors von Voena, Claudia, Menotti, Matteo, Mastini, Cristina, Di Giacomo, Filomena, Longo, Dario Livio, Castella, Barbara, Merlo, Maria Elena Boggio, Ambrogio, Chiara, Wang, Qi, Minero, Valerio Giacomo, Poggio, Teresa, Martinengo, Cinzia, D'Amico, Lucia, Panizza, Elena, Mologni, Luca, Cavallo, Federica, Altruda, Fiorella, Butaney, Mohit, Capelletti, Marzia, Inghirami, Giorgio, Jänne, Pasi A, Chiarle, Roberto

Volltext

Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma von Ambrogio, C., Kohler, J., Zhou, Z., Wang, H., Paranal, R., Capelletti, M., Caffarra, C., Li, S., Lv, Q., Santamaria, D., Westover, K.D., Jänne, P.A.

Volltext

352 Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) mediated signaling and anaplastic large cell lymphoma growth von Riera, L, Lasorsa, E, Ambrogio, C, Surrenti, N, Voena, C, Chiarle, R

Volltext

383 Trapping and silencing of npm-alk in the nucleus is a fundamental event for npm-alk mediated cell transformation von Voena, C, Panizza, E, DiGiacomo, F, Ambrogio, C, Manazza, A.D, Chiarle, R

Volltext